



---

Brancherz

20  
Portfolio 24  
25

Launched in Ramadan 2024 **BUT** Outsourcing/Freelancing since 2009.  
**10+ Years** of pharma industry within different roles, **Partners** with the  
top-notch agencies in MENA, **Certified** team (Med & Tech)

**Together, we craft tailored solutions to empower your  
brand's journey, fueling your growth, igniting your  
competitiveness, and guiding you to new heights!**

**GROW!**

**Our Culture Nurturing Our Purpose!**

Our commitment extends beyond business, we believe in the transformative power of **giving back**.

**Tawasol  
Initiative**

**We dedicated a lifetime**

**3%**

of Brnacherz's profits to empower children for a brighter future.





- Creative concept development**
- Marketing material design Packaging**
- Digital marketing**
- 3D modeling**
- Logos & Brand Identity**
- Video production**
- Medical content creation & Detail Aids**
- Organizational Development& Corporate training**

## Our Success Partners



Alcon




sanofi

Canon



LVMH



Vit&Care

abbvie



BENMUV

# Creative Concepts

## **Visuals & Sketching**

We pride ourselves on our ability to utilize AI tools to craft compelling concepts that not only tell an interesting story but leave a lasting impression!





**THE SWEET TRAP**  
WHAT YOU DON'T SEE  
CAN HARM YOU!



**SHARPEN YOUR FOCUS  
UNLEASH YOUR POTENTIAL!**










RESTORING  
LIFE **COMFORT**



# AMVALAN Precision in Every Dose

Crafted with care, tailored for lasting control in blood pressure management.





Shaikh Khalifa Specialty Hospital - Cardiovascular Department

# **1st Cardiovascular & Critical Care Conference**





# ALCON MASQUERADE BALL





# Marketing Materials Packaging

Each piece is meticulously designed to convey your unique message and to stand out of the clutter.























جَنِيْتَ!





























# Digital Marketing

**One Stop Shop for the digital world!**

Comprehensive suite of services to elevate your brand's online presence and engagement; ensuring seamless and user-friendly digital experiences. Providing valuable digital insights for informed decision-making.











# **3D Models**

**Full Environment Simulation 3D Event items Production Booths Productions**  
crafting captivating 3D environments and lifelike item simulations through  
state-of-the-art rendering techniques.













# Logos & Branding

**Full Environment Simulation 3D Event items Production Booths Productions**  
crafting captivating 3D environments and lifelike item simulations through  
state-of-the-art rendering techniques.

*///gopla*

**USA**


Ai Sports Analytics



*darina*  
HOLIDAYS

**UAE**

Tourism Platform





**UAE**

**Mobile Vet Clinic**






**Pakistan**

Distribution Trading Co.





**GROUNDTEC**  
Piling & Foundation **Contracting**

**UAE**

Contracting Co.



# meet.

**UAE**


Pharma





**UAE**

Business Management





**Egypt**

**Gym**



# **Video Production**

## **Medical illustration Videos and Animated Graphic Motions**

We meticulously combine science with creative storytelling, ensuring that your clients receive engaging and educational content.









# Medical Content Creation & Detail Aids

**Engaging Digital Detail Aids with Medical Precision.**

We craft interactive content that bridges marketing and medicine covering patient education, scientific referencing, localization, research, and CME certification.



**Everolimus: Clinical Trials (BOLERO-2)**

Efficacy Outcomes: Everolimus Combined with an AI Improved PFS in Patients with HR+ ABC Previously Treated with NSAI

Median PFS months (95% CI)  
HR (95% CI)  
value  
ORR, %  
CBR, %

Everolimus PFS: 7.8 months  
Placebo PFS: 3.2 months

Progression-free survival probability

Time (months)

Number at risk

Everolimus + exemestane	Placebo + exemestane
485	239
384	146
318	103
236	61
194	42
147	27
99	17
57	9
42	6
23	2
13	1
10	1
4	0
1	0
0	0

Reference:  
1. Yarchoan, D.A. et al. (2013). "Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 first progression-free survival analysis." *American Journal of Clinical Oncology*. 36(1): 1-7.

<https://doi.org/10.1007/s12325-010-0060-1>

NOVARTIS

Index

Indication

Mechanism

Dosage and Administration

Clinical Trials

AFINITOR® (everolimus) Tablets

Helping Patients Since 2009

AFINITOR® (everolimus) Tablets has delivered efficacy and safety data backed by more than a decade of clinical use. First approved by the FDA in 2009.

NOVARTIS

Clinical Trials

MOA API

**PROMID Trial:** Octreotide Significantly Lengthens Time to Tumour Progression vs Placebo<sup>1</sup>

Placebo, 40 events; median, 8.0 months  
Octreotide LAR, 26 events; median, 14.3 months

No. of patients at risk

Placebo	Octreotide	Placebo
43	42	43
21	30	21
9	19	9
3	16	3
1	15	1
1	10	0
0	10	0
0	9	0
0	9	0
0	6	0
0	5	0
0	3	0
0	1	0
0	0	0
0	0	0
0	0	0
0	0	0
0	0	0

Log-rank test stratified by functional activity: P = .000072, HR = 0.34 (95% CI, 0.20 to 0.59)

Median TTP

Octreotide	Placebo
14.3 months	8.0 months

Progression or Tumour-Related Death, n

Octreotide	Placebo
26	40

Stable Disease At 6 Months, %

Octreotide	Placebo
67	37

LAR, long-acting release; TTP, time to progression.  
Reference: 1. Reubi JC, et al. J Clin Oncol. 2009;27:4659-4666.

**Sandostatin LAR Depot**  
(octreotide acetate) for injectable suspension  
10mg • 20mg • 30mg

**30 Years of Patient Support.\***  
Sandostatin Has Been Helping Patients for Over 30 Years. \*\*

**Patients with Non-Functioning Tumours**

Treatment	Median TTP (Months)
Placebo	5.91
Octreotide LAR 30 mg	28.8

p=0.0039; HR=0.25 (95% CI 0.10-0.59)

**5X Longer than Placebo.**

**Patients with Functioning Tumours**

Treatment	Median TTP (Months)
Placebo	5.45
Octreotide LAR 30 mg	14.26

p=0.0007; HR=0.23 (95% CI 0.09-0.47)

\*For all approved indications  
\*\*includes sandostatin immediate-release injection and sandostatin LAR depot for all approved indications

Acromegaly NET

NOVARTIS API

**ENESTfreedom**

The ENESTfreedom Study (NCT01784068) is a single-arm phase 2 study to specifically **Assess the Feasibility of Treatment for Patients** with CML-CP who achieved **Sustained Molecular Response** during frontline nilotinib.<sup>12</sup>

**About Arterial Thrombotic Events** with ponatinib<sup>3</sup>

**The Primary Endpoint** of each trial is indicated in Red

TKI	Trial	Study arm	Results at 1 year
			CCyR MMR
Imatinib	IRIS <sup>2</sup>	Imatinib 400 mg daily (n=553)	NR 39%
		PN-alpha plus low-dose ara-C (n=553)	NR NR
Dasatinib	DASISION <sup>3</sup>	Dasatinib 100 mg daily (n=258)	77% <sup>a</sup> 43%
		Imatinib 400 mg daily (n=265)	68% <sup>a</sup> 26%
Bosutinib	BFORCE <sup>4</sup>	Bosutinib 400 mg daily (n=268)	77.2% <sup>c</sup> 47.2%
		Imatinib 400 mg daily (n=265)	68.4% 36.9%
Nilotinib	ENESTrd <sup>5a</sup>	Nilotinib 300 mg twice daily (n=252)	80% <sup>b</sup> 44%
	ENESTrd <sup>5a</sup>	Nilotinib 400 mg twice daily (n=282)	78% <sup>b</sup> 43%
	ENESTrd <sup>5a</sup>	Imatinib 400 mg daily (n=283)	65% 22%

**N=215**

abMR was defined as the following (in the last 4 quarterly RQ-PCR assessments): MR<sup>a</sup> in the last assessment; >2 assessments before worse than MR<sup>a</sup>. This analysis was based on a cut-off date of February 3, 2020, at which time all patients who entered the TFR phase had completed 5 years of follow-up, or discontinued from the study.

CML-CP: chronic myeloid leukemia in chronic phase; DMR: deep molecular response; IS: International Scale; MR: major molecular response; bCR-ABP<sup>b</sup>: <0.1%; MR<sup>b</sup>; bCR-ABP<sup>b</sup>: <0.01%. MR<sup>c</sup>; bCR-ABP<sup>c</sup>: <0.0025%. RQ-PCR: real-time quantitative polymerase chain reaction; TFR: long-term follow-up; TFR phase: long-term follow-up phase.

**Enroll**

RQ-PCR (standardized to the IS) every 12 weeks

Consolidation Phase (52 weeks) Sustained DMb

RQ-PCR (standardized every 4 weeks for 71 weeks, and then every 6 weeks for 8 weeks)

TFR Phase

**Faster, Deeper & Durable**

Among 2<sup>nd</sup> generation TKIs that treat newly diagnosed patients with Ph+ CML-CP

**ONLY TASIGNA HAS BEEN STUDIED FOR 10 YEARS**

**NOVARTIS**

**Clinical Trials** **Patient Profiles**

# **Organizational Development & Corporate training**

Our comprehensive program includes engaging workshops and dynamic team-building activities designed to enhance skills, foster collaboration, and drive organizational success.

**Transform your team with Brancherz!**

# CERTIFIED TEAM!



**Developing customized training sessions about different business & self-development topics, among which:**

- Leadership: Coaching & Feedback Approach
- Advanced Presentation Skills & Public Speaking
- Psychological Safety At The Workplace **BEST SELLER**
- Creativity & Mind Mapping
- Customer Experience Journey
- Emotional Selling Skills
- Risk & Crisis Management
- Negotiation Skills

# Psychological Safety At The Workplace

BEST  
SELLER



**Join a series of interactive workshops,  
to learn more about:**

- What is Psychological Safety at the Workplace?
- Impacts on Performance Standards, Organizational Culture & Business Goals.
- Defining & overcoming Obstacles in the way of P.S..
- Behaviors & Factors to foster a Psychologically Safe Work Environment.
- The 4 Stages to achieve Psychological Safety.
- The Way Forward: Psychological Safety Action Plan:  
From Theory Practice.

**Hala** us, & we will **Hala** you back immediatly!

[info@brancherz.com](mailto:info@brancherz.com)

+971 52 147 1307





# shokran!